|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1: Functional outcome measures across symptom duration and three years of follow-up by demographics and clinical factors** | | | | | | | | | |
| **Characteristic** | **NSAD** | | **ACTIVLIM** | | **10 Meter Walk Test** | | **6 Minute Walk Test** | |
| β (95% CI) | p-value  (trajectory) | β (95% CI) | p-value  (trajectory) | β (95% CI) | p-value  (trajectory) | β (95% CI) | p-value  (trajectory) |
| **Symptom Duration**a | | | | | | | | | |
| Symptom duration | -1.60 (-1.88, -1.31)\* | **0.0003** | -0.78 (-0.88, -0.67)\* | **0.03** | -0.08 (-0.10, -0.06)\* | **< 0.0001** | -0.04 (-0.05, -0.03)\* | **0.003** |
| Race  White  Asian  Hispanic  Other | Ref.  -4.43 (-10.25, 1.40)  -5.58 (-11.93, 0.77)  -3.52 (-9.59, 2.55) | 0.85 | Ref.  -0.71 (-3.85, 2.43)  -0.97 (-4.22, 2.27)  -0.28 (-4.44, 3.87) | 0.65 | Ref.  -0.53 (-0.89, -0.16)\*  -0.30 (-0.69, 0.08)  -0.18 (-0.56, 0.21) | 0.11 | Ref.  -0.25 (-0.42, -0.08)\*  -0.15 (-0.37, 0.07)  -0.09 (-0.31, 0.13) | 0.44 |
| Sex  Male  Female | Ref.  4.60 (0.90, 8.31)\* | 0.17 | Ref.  1.76 (-0.51, 4.03) | 0.66 | Ref.  0.17 (-0.09, 0.42) | 0.19 | Ref.  0.12 (-0.01, 0.25) | 0.86 |
| Age at onset | 0.26 (0.06, 0.45)\* | **0.04** | 0.07 (-0.04, 0.19) | 0.48 | 0.006 (-0.007, 0.02) | 0.85 | 0.004 (-0.002, 0.01) | 0.71 |
| Teen exercise level  None  Low  Moderate  High | Ref.  -0.35 (-6.37, 5.68)  -2.45 (-7.67, 2.78)  -2.97 (-7.48, 1.54) | 0.58 | Ref.  -1.42 (-4.94, 2.10)  -1.28 (-4.34, 1.77)  -2.59 (-5.35, 0.17) | 0.60 | Ref.  -0.07 (-0.46, 0.31)  -0.05 (-0.38, 0.28)  -0.08 (-0.38, 0.22) | 0.08 | Ref.  -0.06 (-0.27, 0.15)  -0.04 (-0.21, 0.14)  -0.09 (-0.23, 0.06) | 0.21 |
| **Study Follow-up**b | | | | | | | | | |
| Follow-up time (in months) | -0.14 (-0.17, -0.11)\* | -- | -0.09 (-0.11, -0.08)\* | **--** | -0.01 (-0.01, -0.009)\* | -- | -0.01 (-0.01, -0.004)\* | -- |
| Age at baseline | -0.44 (-0.63, -0.25)\* | **0.002** | -0.35 (-0.44, -0.25)\* | 0.20 | -0.03 (-0.04, -0.02)\* | **0.04** | -0.02 (-0.02, -0.01)\* | 0.76 |
| Race  White  Asian  Hispanic  Other | Ref.  -4.07 (-10.12, 1.98)  -2.95 (-10.51, 4.60)  -7.11 (-12.89, -1.33)\* | 0.84 | Ref.  -0.09 (-3.41, 3.22)  -0.08 (-4.11, 3.95)  -1.77 (-5.79, 2.24) | 0.41 | Ref.  -0.39 (-0.73, -0.06)\*  -0.21 (-0.60, 0.18)  -0.52 (-0.79, -0.24)\* | 0.14 | Ref.  -0.22 (-0.41, -0.04)\*  -0.08 (-0.31, 0.16)  -0.20 (-0.39, -0.01)\* | 0.38 |
| Sex  Male  Female | Ref.  3.27 (-1.46, 8.00) | 0.14 | Ref.  1.07 (-1.51, 3.64) | 0.19 | Ref.  0.05 (-0.23, 0.34) | 0.22 | Ref.  0.07 (-0.08, 0.22) | 0.42 |
| Age at onset | 1.16 (0.85, 1.46)\* | 0.06 | 0.68 (0.51, 0.84)\* | 0.30 | 0.05 (0.03, 0.07)\* | 0.98 | 0.03 (0.02, 0.04)\* | 0.73 |
| Symptom duration (at baseline) | -1.16 (-1.46, -0.85)\* | **0.002** | -0.68 (-0.84, -0.51)\* | 0.20 | -0.05 (-0.07, -0.03)\* | **0.006** | -0.03 (-0.04, -0.02)\* | 0.63 |
| TUG velocity at baseline (0.01 unit) | 2.22 (1.96, 2.49)\* | 0.17 | 1.10 (0.92, 1.27)\* | **0.03** | 0.12 (0.11, 0.14)\* | 0.08 | 0.07 (0.06, 0.08)\* | 0.08 |
| RFF velocity at baseline (0.01 unit) | 0.77 (0.57, 0.98)\* | 0.46 | 0.35 (0.24, 0.46)\* | **0.001** | 0.04 (0.04, 0.05)\* | 0.08 | 0.02 (0.02, 0.03)\* | **0.003** |
| a Estimates from GEE models controlling for symptom duration; no differences based on clinical diagnosis noted (data not shown)  b Estimates from GEE models controlling for age at baseline; no differences based on clinical diagnosis or teen exercise noted (data not shown)  \* Significant or significantly different from reference category at p < 0.05  TUG = Timed Up and Go; RFF = Rise From Floor | | | | | | | | | |